A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Inclusion Criteria:

- Confirmed clinical diagnosis of ulcerative colitis (UC) at least 3 months before
screening

- Moderately to severely active UC as defined by Mayo score

- History of inadequate response to or failure to tolerate conventional therapy

- Has screening laboratory test results within the study protocol defined parameters

- A woman of childbearing potential must have a negative highly sensitive serum (beta
human chorionic gonadotropin) pregnancy test result at screening and a negative urine
pregnancy test result at Week 0

Exclusion Criteria:

- Has severe extensive colitis as defined in the study protocol

- Has UC limited to the rectum only or to less than (<) 20 centimeter (cm) of the colon

- Has a history of latent or active granulomatous infection, including histoplasmosis or
coccidioidomycosis, before screening

- Has any known malignancy or has a history of malignancy (with the exception of basal
cell carcinoma; squamous cell carcinoma in situ of the skin; or cervical carcinoma in
situ that has been treated with no evidence of recurrence; or squamous cell carcinoma
of the skin that has been treated with no evidence of recurrence within 5 years before
screening)

- Has known allergies, hypersensitivity, or intolerance to guselkumab or golimumab or
their excipients